ERBB2 and neoplasm: The authors indicated that this high proportion of ERBB2 mutations in HR-positive patients indicates the need to assess for resistant mutations in this population and highlighted the current limitation to detect CNAs in ctDNA due to the very low tumour fraction found in plasma (Table 1).